Target ALS

Behind every ALS discovery is a scientist who had the right sample, dataset, or tool at the right time. That's what our Research Cores are built for. See how our Longitudinal Biofluids Core and Postmortem Tissue Core create access to invaluable resources: ow.ly/zGJh50ZnyjR

We're pulling back the curtain on the research, breakthroughs, and collaboration driving our mission forward. RSVP now: zoom.us/webinar/regist… #EveryoneLives #TALS2026AnnualMeeting #Webinar #ALS #ALSResearch

Biomarkers, measurable indicators of what's happening inside the body, are essential for diagnosing disease, tracking progression, and evaluating whether treatments are working. At this year’s annual meeting, teams shared progress on biomarker discovery: targetals.org/biomarkers-202…

Happy birthday to our founder, Dan Doctoroff. He founded Target ALS to accelerate research so that effective treatments become inevitable. We're grateful for his leadership, his impatience for progress, and his unwavering belief that we will build a world where #EveryoneLives.

Today, there is no definitive test to diagnose ALS. Dr. La Spada and his consortium are developing a blood-based biomarker that could fundamentally change that. Read more about this game-changing work and more in our Annual Meeting Impact Report: ow.ly/AxvA50Zllj9

Chris Johnson's decision to share his diagnosis has brought the #ALSIceBucketChallenge back into the spotlight, and we're inviting you to join in to raise awareness and funds. Research is the only way to build a world where #EveryoneLives — donate today: ow.ly/ibql50Zmay7

The Target ALS fund-enable-conduct model ensures that good science doesn't slip through the cracks, that the best ideas have what they need to move forward, and that the people working on them aren't doing it alone. See what we've made possible: ow.ly/FFN350ZllgR

Reliable biomarkers could transform how ALS is diagnosed, tracked, and treated. At our Annual Meeting, leading researchers and industry experts discussed biomarker science and how we can make more progress. See the panel + learn about biomarker projects: targetals.org/biomarkers-202…

At the 2026 Target ALS Annual Meeting, researcher Nicholas Ashton described how his Target ALS-funded collaboration is closing a research gap and accelerating biomarker development. This is collaboration in action. See more on advances in biomarkers: ow.ly/TcvG50Zlk6N

At the 2026 Target ALS Annual Meeting, Dr. Juliana Acosta-Uribe presented findings from Target ALS-funded fieldwork tracking families with ALS and FTD across Colombia — with implications well beyond a single diagnosis. See the project: targetals.org/colombia-famil…

ALS is a disease of the motor neurons. However, emerging research from Target ALS-funded scientists reveals a complex breakdown that signals a meaningful shift in how the immune system may play an active role in neurodegeneration. Read more: ow.ly/g50a50ZjoEe

Target ALS VP of Scientific Programs Amy Easton reflected on one of the Annual Meeting’s most exciting moments: promising interim results from QurAlis’s Phase 1/2 clinical trial. Explore more from the 2026 Annual Meeting: ow.ly/qnet50Zjnci

The 2026 Annual Meeting Impact Report is here. New clinical trial data. Breakthroughs in biomarker development. A new generation of precision therapies. Explore and download the report: targetals.org/2026-annual-me… #EveryoneLives

Dr. Rosa Rademakers, who was part of the team that first identified C9orf72 as a driver of ALS and FTD is now leading a consortium purpose-built for that challenge. Get the full story and more in the Annual Meeting Impact Report dropping tomorrow: targetals.org/join-us/

A major milestone in our Global Natural History Study: 75% of the control arm is now enrolled. This means the field is closer to having a robust collection of biofluid samples and high-quality datasets that aren’t siloed to just one lab. Learn more: ow.ly/zspy50Zg63Q

Target ALS CEO Manish Raisinghani reflects on what the field looked like when the organization was founded—and how we've changed things, especially with our Annual Meeting. Learn more by signing up to receive our Annual Meeting Impact Report: ow.ly/Elp950Zg62h

The poster session is one of the most distinctive elements of the Target ALS Annual Meeting. It's a unique forum for all to meet researchers, forge connections, and dig into the details. Explore more in the Annual Meeting Impact report dropping June 30: ow.ly/Qi5x50Zg61H

AI and machine learning will soon change the future of ALS research. Target ALS VP of Scientific Programs Dr. Amy Easton shares her perspective on what's ahead in our Annual Meeting Impact Report. Sign up to see her take: ow.ly/Ty7s50Zg60l

TDP-43 pathology is seen in nearly every case of ALS. At this year's Annual Meeting, multiple research teams shared progress in TDP-43 biomarker development. The full story is in the 2026 Annual Meeting Impact Report, out June 30: ow.ly/kJsA50Zet6L

In 2020, we funded a consortium led by QurAlis to study a drug target. Three years later, they launched a clinical trial. Today, they have interim results. Watch to learn more and get a full breakdown in our upcoming Annual Meeting Impact Report: ow.ly/Jjg750Zet3z